Personalized Treatments, Overcoming Resistance Is Needed in Melanoma

Source: Oncology Nursing News, November 2020

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, Georgina Long, AO, BSc, PhD, MBBS, FRACPP, FAHMS, said that the next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

Moreover, ongoing first-line studies will show a small, if any, incremental benefit in patients with advanced disease, Long projected in a presentation during the virtual 17th International Congress of the Society for Melanoma Research.1

“We have benchmarks for our standard treatments; we can explore more new, novel therapies, look at [patients’] pathologic complete response rates within 6 weeks, and then make decisions on whether they need further development.

READ THE ORIGINAL FULL ARTICLE